A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
The reason for this study is to determine the long-term efficacy and safety of the study drug
 mirikizumab in participants with Crohn's disease.
Inclusion Criteria:

 -  Participants must have completed study I6T-MC-AMAG (NCT02891226) or study I6T-MC-AMAM
 (NCT03926130)

 -  If female, participant must meet the contraception requirements

 Exclusion Criteria:

 -  Participants must not have developed a new condition, including cancer in the previous
 study (I6T-MC-AMAG or I6T-MC-AMAM)

 -  Participants must not have any important infections including, but not limited to,
 hepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB) during either
 previous study

 -  Participants may not have received surgery for Crohn's disease in the originator study
 or are likely to require surgery for treatment of Crohn's disease during the study

 -  Participants must not have developed adenomatous polyps during the originator study
 that have not been removed prior to the start of this study